Reflecting these positive developments, Goldman Sachs has raised its 12-month target price for Everest Medicines to HK$48.32, nearly doubling from the previous HK$24.50. The upgrade factors in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback